<DOC>
	<DOCNO>NCT01488331</DOCNO>
	<brief_summary>This prospective , multi-center , observational study assess progression-free survival safety patient locally advanced metastatic non-small cell lung cancer treat Tarceva ( erlotinib ) disease progress least 9 month . Data collect 24 month .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Diagnosis locally advance metastatic nonsmall cell lung cancer ( NSCLC , stage III/IV ) Treatment Tarceva monotherapy progress least 9 month date study start Not agree followedup ( maximum 24 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>